Latest News

The quantum computing company will likely remain a volatile stock this year.

Warren Buffett sold stock for a 10th-straight quarter, but just barely. The oracle or Omaha's retirement hit Berkshire Hathaway shares.

The dollar has begun the new week under pressure, though many financial centers are closed today.

In response to the academic funding cuts in the US under Trump, France and the EU are preparing to roll out incentives to attract researchers.

Henry Schein affirms 2025 EPS outlook and projects 2%–4% sales growth, recording $25 million in restructuring costs in Q1 2025.

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks.

Trump claims he might personally phone CEOs for business moves he dislikes, using this tactic on Amazon's Bezos over tariff disclosures.

The strong Canadian Dollar has recently pushed the price to multi-month lows, but support is firming up above the big quarter-number at $1.3750.

Palantir Technologies Inc (NASDAQ:PLTR) shares are trending on Monday ahead of earnings after the bell. Here's a look at what you need to know.

Freshpet Inc. (NASDAQ: FRPT) stock dipped in premarket trading after posting a Q1 FY25 earnings miss. Despite revenue growth of 17.6% to $263.25 million, the company reported an EPS loss of $(0.26), missing estimates. Higher operating costs led to an $11.5 million loss. Freshpet also cut its full-year sales forecast amid weaker-than-expected growth and ongoing economic pressures.

HHH shares surge premarket as Pershing Square invests $900M for 9 million shares, representing 48% premium. Ackman appointed as exec chairman.

Gold price rallies more than 2% on Monday with nervousness towards the Fed interest-rate decision.

Analog chips maker onsemi (NASDAQ:ON) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 22.4% year on year to $1.45 billion. Guidance for next quarter’s revenue was optimistic at $1.45 billion at the midpoint, 2.5% above analysts’ estimates. Its non-GAAP profit of $0.55 per share was 9.6% above analysts’ consensus estimates.

BioCryst now expects global net Orladeyo revenue to be between $580 million and $600 million for the full year, up from its previous guidance of between $535 million and $550 million.